Cargando…

SARS-CoV-2 Post Vaccinated Adverse Effects and Efficacy in the Egyptian Population

Vaccines are the solution to overcome SARS-CoV-2. This study aimed to determine the post-Sinopharm vaccine safety-profile and immunity through antibody titers. Data were collected using a structured questionnaire from Egyptian participants who received two doses of Sinopharm vaccine. Data were divid...

Descripción completa

Detalles Bibliográficos
Autores principales: Elgendy, Marwa O., El-Gendy, Ahmed O., Alzarea, Abdulaziz Ibrahim, Mahmoud, Sarah, Alqahtani, Saad S., Fahmy, Alzhraa M., El-Seedi, Hesham R., Sayed, Ahmed M., Alatawi, Ahmed D., Abdelrahim, Mohamed E. A., Alanazi, Abdullah S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779046/
https://www.ncbi.nlm.nih.gov/pubmed/35062679
http://dx.doi.org/10.3390/vaccines10010018
_version_ 1784637475106324480
author Elgendy, Marwa O.
El-Gendy, Ahmed O.
Alzarea, Abdulaziz Ibrahim
Mahmoud, Sarah
Alqahtani, Saad S.
Fahmy, Alzhraa M.
El-Seedi, Hesham R.
Sayed, Ahmed M.
Alatawi, Ahmed D.
Abdelrahim, Mohamed E. A.
Alanazi, Abdullah S.
author_facet Elgendy, Marwa O.
El-Gendy, Ahmed O.
Alzarea, Abdulaziz Ibrahim
Mahmoud, Sarah
Alqahtani, Saad S.
Fahmy, Alzhraa M.
El-Seedi, Hesham R.
Sayed, Ahmed M.
Alatawi, Ahmed D.
Abdelrahim, Mohamed E. A.
Alanazi, Abdullah S.
author_sort Elgendy, Marwa O.
collection PubMed
description Vaccines are the solution to overcome SARS-CoV-2. This study aimed to determine the post-Sinopharm vaccine safety-profile and immunity through antibody titers. Data were collected using a structured questionnaire from Egyptian participants who received two doses of Sinopharm vaccine. Data were divided into three parts, the first and second parts were to detect participants’ post-first and second dose symptoms and practices, and the third for the results of IgG anti spike protein antibodies test and laboratory tests. Pain, redness, swelling at the injection site, headache, fatigue, and lethargy were the most common post-vaccine symptoms for both first and second doses. Most of the participants felt mild or no symptoms after vaccination. The symptoms started mostly during the first day post-vaccination and lasted for no more than two days. Forty-nine percent of the participants resulted in positive antibodies tests on day 18 post-vaccination. The average antibody level for vaccinated participants with past SARS-CoV-2 infection was much higher than that for non-past infected participants. These vaccines’ administration methods need to be reevaluated by changing the dose, dose interval, adding a third dose, or mixing it with other vaccines with different techniques to improve their protection rates. Further studies are required to validate this finding.
format Online
Article
Text
id pubmed-8779046
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87790462022-01-22 SARS-CoV-2 Post Vaccinated Adverse Effects and Efficacy in the Egyptian Population Elgendy, Marwa O. El-Gendy, Ahmed O. Alzarea, Abdulaziz Ibrahim Mahmoud, Sarah Alqahtani, Saad S. Fahmy, Alzhraa M. El-Seedi, Hesham R. Sayed, Ahmed M. Alatawi, Ahmed D. Abdelrahim, Mohamed E. A. Alanazi, Abdullah S. Vaccines (Basel) Article Vaccines are the solution to overcome SARS-CoV-2. This study aimed to determine the post-Sinopharm vaccine safety-profile and immunity through antibody titers. Data were collected using a structured questionnaire from Egyptian participants who received two doses of Sinopharm vaccine. Data were divided into three parts, the first and second parts were to detect participants’ post-first and second dose symptoms and practices, and the third for the results of IgG anti spike protein antibodies test and laboratory tests. Pain, redness, swelling at the injection site, headache, fatigue, and lethargy were the most common post-vaccine symptoms for both first and second doses. Most of the participants felt mild or no symptoms after vaccination. The symptoms started mostly during the first day post-vaccination and lasted for no more than two days. Forty-nine percent of the participants resulted in positive antibodies tests on day 18 post-vaccination. The average antibody level for vaccinated participants with past SARS-CoV-2 infection was much higher than that for non-past infected participants. These vaccines’ administration methods need to be reevaluated by changing the dose, dose interval, adding a third dose, or mixing it with other vaccines with different techniques to improve their protection rates. Further studies are required to validate this finding. MDPI 2021-12-24 /pmc/articles/PMC8779046/ /pubmed/35062679 http://dx.doi.org/10.3390/vaccines10010018 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Elgendy, Marwa O.
El-Gendy, Ahmed O.
Alzarea, Abdulaziz Ibrahim
Mahmoud, Sarah
Alqahtani, Saad S.
Fahmy, Alzhraa M.
El-Seedi, Hesham R.
Sayed, Ahmed M.
Alatawi, Ahmed D.
Abdelrahim, Mohamed E. A.
Alanazi, Abdullah S.
SARS-CoV-2 Post Vaccinated Adverse Effects and Efficacy in the Egyptian Population
title SARS-CoV-2 Post Vaccinated Adverse Effects and Efficacy in the Egyptian Population
title_full SARS-CoV-2 Post Vaccinated Adverse Effects and Efficacy in the Egyptian Population
title_fullStr SARS-CoV-2 Post Vaccinated Adverse Effects and Efficacy in the Egyptian Population
title_full_unstemmed SARS-CoV-2 Post Vaccinated Adverse Effects and Efficacy in the Egyptian Population
title_short SARS-CoV-2 Post Vaccinated Adverse Effects and Efficacy in the Egyptian Population
title_sort sars-cov-2 post vaccinated adverse effects and efficacy in the egyptian population
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779046/
https://www.ncbi.nlm.nih.gov/pubmed/35062679
http://dx.doi.org/10.3390/vaccines10010018
work_keys_str_mv AT elgendymarwao sarscov2postvaccinatedadverseeffectsandefficacyintheegyptianpopulation
AT elgendyahmedo sarscov2postvaccinatedadverseeffectsandefficacyintheegyptianpopulation
AT alzareaabdulazizibrahim sarscov2postvaccinatedadverseeffectsandefficacyintheegyptianpopulation
AT mahmoudsarah sarscov2postvaccinatedadverseeffectsandefficacyintheegyptianpopulation
AT alqahtanisaads sarscov2postvaccinatedadverseeffectsandefficacyintheegyptianpopulation
AT fahmyalzhraam sarscov2postvaccinatedadverseeffectsandefficacyintheegyptianpopulation
AT elseediheshamr sarscov2postvaccinatedadverseeffectsandefficacyintheegyptianpopulation
AT sayedahmedm sarscov2postvaccinatedadverseeffectsandefficacyintheegyptianpopulation
AT alatawiahmedd sarscov2postvaccinatedadverseeffectsandefficacyintheegyptianpopulation
AT abdelrahimmohamedea sarscov2postvaccinatedadverseeffectsandefficacyintheegyptianpopulation
AT alanaziabdullahs sarscov2postvaccinatedadverseeffectsandefficacyintheegyptianpopulation